MANNKIND CORP Proceeds from Insurance Settlement, Investing Activities
MANNKIND CORP (MNKD) reported Proceeds from Insurance Settlement, Investing Activities of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromInsuranceSettlementInvestingActivities · last filed 2026-02-26
- MANNKIND CORP proceeds from insurance settlement, investing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP proceeds from insurance settlement, investing activities for the quarter ending 2024-12-31 was $0.00.
- MANNKIND CORP proceeds from insurance settlement, investing activities for the quarter ending 2024-09-30 was $0.00.
- MANNKIND CORP proceeds from insurance settlement, investing activities for the quarter ending 2024-06-30 was $0.00.
- MANNKIND CORP proceeds from insurance settlement, investing activities for fiscal 2024 was $396.00K, a 3.66% increase from fiscal 2023.
- MANNKIND CORP proceeds from insurance settlement, investing activities for fiscal 2023 was $382.00K.
| Period end | Proceeds from Insurance Settlement, Investing Activities 3 month | Proceeds from Insurance Settlement, Investing Activities 6 month | Proceeds from Insurance Settlement, Investing Activities 9 month | Proceeds from Insurance Settlement, Investing Activities 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $396.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $396.00K 10-Q · filed 2025-11-05 | $396.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $396.00K 10-Q · filed 2025-08-06 | $396.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $396.00K 10-Q · filed 2025-05-08 | $396.00K derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $382.00K 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $382.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |